



San Francisco Monthly STI Report

Data for December, 2021
Report prepared February 11, 2022

Table 1. STIs among residents, December, 2021. Female syphilis cases include patients assigned as female at birth.

	2021		2020	
	month	YTD	month	YTD
Gonorrhea	512	5,269	372	4,104
Male rectal gonorrhea	181	1,812	98	1,154
Chlamydia	567	6,185	428	5,732
Male rectal chlamydia	198	1,867	115	1,563
Syphilis (adult total)	147	1,922	158	1,687
Primary & secondary	35	409	29	502
Early latent	68	830	82	744
Unknown latent	12	239	13	196
Late latent	32	444	34	245
Neurosyphilis	1	24	2	18
Congenital syphilis	1	2	0	5
Female syphilis	15	195	14	171




Figure 1. Monthly STI trends for San Francisco. Syphilis cases different scale.

Table 2. Selected STI cases and rates for San Francisco by age and race/ethnicity, 2021 through December. Rates equal cases per 100,000 residents per year based on 2010 US Census Data.

	(All races)		Asian/PI		African American		Hispanic		White	
	cases	rate	cases	rate	cases	rate	cases	rate	cases	rate
<i>All ages</i>										
Chlamydia	6,185	768.1	663	249.5	717	1,532.7	1,027	843.4	1,644	487.2
Gonorrhea	5,269	654.3	485	182.5	666	1,423.7	966	793.3	1,951	578.2
Early syphilis	1,239	153.9	137	51.6	138	295.0	291	239.0	501	148.5
<i>Under 20 yrs</i>										
Chlamydia	435	782.5	31	140.0	108	2,296.4	73	577.0	37	301.8
Gonorrhea	106	190.7	8	36.1	32	680.4	16	126.5	11	89.7
Early syphilis	7	12.6	0	0.0	1	21.3	3	23.7	0	0.0

Table 3. HIV testing among City Clinic patients, December, 2021.

	2021		2020	
	month	YTD	month	YTD
Tests	339	3,489	214	2,670
Antibody positive	4	37	2	37
Acute HIV infection	0	5	0	2

Note: All statistics are provisional until the annual report is released for the year. Morbidity is based on date of diagnosis. Totals for past months may change due to delays in reporting from labs and providers.




Figure 2. City Clinic visits by gender and orientation.




Figure 3. Average number of recent* sex partners for City Clinic visits by gender and sexual orientation.

*Recall period is 3 months.

Exciting PrEP Updates: New CDC Guidelines and low-cost generic PrEP now available

On December 8, 2021, the Centers for Disease Control and Prevention (CDC) released its updated [Clinical Practice Guideline for Preexposure Prophylaxis for HIV Prevention](#) and [Clinical Providers' Supplement](#). Updates from the guidelines include:

- 1) A recommendation to inform **all** sexually active adults and adolescents about PrEP;
- 2) New HIV testing algorithm for people who have taken PrEP medications in the past 3 months, including the recommendation to add HIV-1 RNA (viral load) testing;
- 3) Daily emtricitabine/tenofovir alafenamide (Descovy®) as a PrEP option for men and trans women;
- 4) Decreased frequency of required kidney function screening: assessing eCrCl every 12 months for those <50 or with eCrCl > 90 at initiation, every 6 months for all others;
- 5) Protocol for offering same day PrEP initiation;
- 6) Protocol for offering 2-1-1 ("on demand") emtricitabine/tenofovir disoproxil fumarate (Truvada®) PrEP to men who have sex with men and trans women; and
- 7) A new section on long-acting injectable cabotegravir, which was recently FDA approved for HIV prevention.

Emtricitabine/tenofovir disoproxil fumarate has been [available as a generic medication](#) since September 30, 2020, further facilitating access to free or low-cost HIV PrEP for all.

The [SF City Clinic website](#) has resources to help with PrEP prescribing including a [provider guide](#) and [patient educational handout](#). If you would like help from SFDPH with how to prescribe PrEP or get out-of-pocket costs covered, please contact the City Clinic Biomedical Prevention Coordinator at montica.levy@sfdph.org.

Thank you for prescribing PrEP and helping to prevent HIV!